Incyte (INCY) Q3 2025 Earnings
How Did INCY Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: −0.53%.
Did INCY Beat Earnings? Q3 2025 Results
Yes. Incyte reported Q3 2025 earnings of $2.26 a share on Oct 28, 2025, beating the $1.64 consensus estimate by 38.0%. Revenue was $1.4B against a $1.3B estimate.
Incyte delivered a standout third quarter, posting non-GAAP diluted EPS of $2.26 against a consensus estimate of $1.64, a beat of 38.04%, while revenue of $1.37 billion topped expectations by 8.96% and grew 20.1% year over year, cementing the company's position as one of the stronger performers in immuno-oncology this reporting season. The primary engine behind the results was broad-based product momentum, with Jakafi demand accelerating across all approved indications and Niktimvo gaining commercial traction following its recent launch; net product revenues climbed 19% to $1.15 billion. Profitability also benefited from the absence of a $100 million MacroGenics milestone payment that had weighed on the year-ago period, helping GAAP operating income jump 204% to $443.52 million. Management responded to the quarter's strength by raising full-year 2025 net product revenue guidance to $4.23 billion to $4.32 billion, with Jakafi guidance lifted to $3.05 billion to $3.08 billion, while cash on hand grew to $2.93 billion, providing a firm foundation for continued pipeline investment.
- 10% increase in Jakafi paid demand across all indications
- Opzelura growth driven by increased patient demand and refills in both atopic dermatitis and vitiligo
- Strong initial Niktimvo launch uptake, up 27% sequentially
- Milestone and contract revenues increased to $45 million from $18 million in prior year quarter
- Lower R&D expenses due to absence of $100 million MacroGenics milestone payment from Q3 2024
“Our third-quarter results demonstrate strong growth across our product portfolio, with net product revenues increasing 19% year-over-year, which highlights the momentum in our business and effective commercial execution.”
Incyte CEO, on the earnings call
What Was Incyte's Outlook in Q3 2025?
Incyte raised its full-year 2025 net product revenue guidance to $4.23–$4.32 billion from the prior $4.13–$4.24 billion range, driven by higher demand for Jakafi (raised to $3.050–$3.075 billion) and other hematology/oncology products (raised to $550–$575 million). Opzelura guidance of $630–$670 million is maintained. The company reaffirmed all expense guidance categories. On the pipeline, regulatory submissions for povorcitinib in HS are expected in the EU by year-end 2025 and in the U.S. by early 2026. A registrational program for INCA33890 in MSS CRC is planned for 2026. Ruxolitinib XR bioequivalence data submission to the FDA is on track for Q4 2025. Phase 3 data for tafasitamab in first-line DLBCL is anticipated around year-end 2025.
INCY YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.4B | $1.1B | +20.1% |
| Operating Income | $443.5M | $169.5M | +161.7% |
| Net Income | $424.2M | $106.5M | +298.5% |
INCY Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.